ARS Pharmaceuticals Inc. (SPRY)
NASDAQ: SPRY
· Real-Time Price · USD
9.44
-0.10 (-1.05%)
At close: Sep 26, 2025, 11:06 AM
-1.05% (1D)
| Bid | 6.81 |
| Market Cap | 922.16M |
| Revenue (ttm) | 112.34M |
| Net Income (ttm) | -48.02M |
| EPS (ttm) | -0.48 |
| PE Ratio (ttm) | -19.67 |
| Forward PE | -11.89 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 12.08 |
| Volume | 455,705 |
| Avg. Volume (20D) | 2,182,942 |
| Open | 9.53 |
| Previous Close | 9.54 |
| Day's Range | 9.41 - 9.63 |
| 52-Week Range | 9.34 - 18.90 |
| Beta | 0.92 |
| Ex-Dividend Date | n/a |
About SPRY
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SPRY
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SPRY stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsARS Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 12, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-5.04%
ARS Pharmaceuticals shares are trading lower follo...
Unlock content with
Pro Subscription
4 months ago
+11.48%
ARS Pharmaceuticals shares are trading higher on possible continued strength after reporting a Q1 revenue beat earlier mid-week.
1 month ago · seekingalpha.com
ARS Pharmaceuticals, Inc. (SPRY) Q2 2025 Earnings Call TranscriptARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q2 2025 Earnings Conference Call August 13, 2025 8:30 AM ET Company Participants Eric Karas - Chief Commercial Officer Justin Chakma - Chief Business Officer K...
